A Phase 1/2, Prospective, Randomized, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 10-Valent Pneumococcal Conjugate Vaccine in Healthy Young Adults, Toddlers, and Infants

Trial Profile

A Phase 1/2, Prospective, Randomized, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 10-Valent Pneumococcal Conjugate Vaccine in Healthy Young Adults, Toddlers, and Infants

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Dec 2016

At a glance

  • Drugs SIILPCV10 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
  • Indications Pneumococcal infections
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 13 Sep 2016 Planned End Date changed from 1 May 2016 to 1 Oct 2016.
    • 13 Sep 2016 Planned primary completion date changed from 1 May 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top